Epygenix Therapeutics, Inc. ("Epygenix"), a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the Company's Investigational New Drug ("IND") application to initiate A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome (LGS). LGS is a rare epileptic encephalopathy presenting in childhood with intractable seizures.
